J Korean Soc Pediatr Endocrinol Search


Ann Pediatr Endocrinol Metab > Accepted Articles
DOI: https://doi.org/10.6065/apem.2346132.066    [Accepted] Published online January 29, 2024.
Long-term efficacy of triptorelin 3-month depot in girls with central precocious puberty
Kyu Hyun Park1  , Si-Hwa Gwag1, Yu Jin Kim1, Lindsey Yoojin Chung2, Eungu Kang1, Hyo-Kyoung Nam1, Young-Jun Rhie1, Kee-Hyoung Lee1 
1Department of Pediatrics, Korea University College of Medicine, Seoul, Korea
2Department of Pediatrics, Myoungji Hospital, Goyang, Korea
Address for correspondence:  Kee-Hyoung Lee
Email: doclee@korea.ac.kr
Received: June 30, 2023   Revised: August 7, 2023   Accepted: August 26, 2023
Three-month gonadotropin-releasing hormone agonists (GnRHa) are expected to achieve better compliance in patients with central precocious puberty (CPP). However, 1-month depot remains the dominant choice for conventional treatment worldwide. Our study aimed to investigate the long-term efficacy of a 3-month GnRHa for CPP treatment.
In this retrospective study, 69 Korean girls with CPP were prescribed with either triptorelin pamoate (TP) 3-month depot (n = 29) or triptorelin acetate (TA) 1-month depot (n = 40) and were followed up for 1 year after the end of treatment. Auxological, radiological, and biochemical data were collected every 6 months.
Baseline characteristics of the subjects were similar between the two groups. In the TP 3-month depot group, 27/29 (93.1 %) of patients exhibited suppressed LH levels (below 2.5 IU/L) after 6 months of treatment, and this suppression level was reserved until the final injection. The degree of bone age advancement in the TP 3-month depot group decreased from 1.8 ± 0.4 years at the start of treatment to 0.6 ± 0.5 years at 1 year post-treatment. The gain in predicted adult height (PAH) at 1 year after the end of treatment was similar between the TP 3-month and TA 1-month depot groups (5.2 ± 3.1 and 5.3 ± 2.4 cm, respectively; P = 0.875).
The 3-month depot of triptorelin effectively inhibited gonadal and sex hormones, suppressed bone maturation, and increased PAH. For the patients’ convenience, we suggest a 3-month GnRHa regimen as a promising CPP treatment option.
Keywords: Central precocious puberty, Gonadotropin-releasing hormone, Triptorelin pamoate


Browse all articles >

Editorial Office
501-107, 30 Seocho-daero 74-gil, Seocho-gu, Seoul 06622, Republic of Korea
Tel: +82-2-3471-4268    Fax: +82-2-3471-4269    E-mail: editor@e-apem.org                

Copyright © 2024 by Korean Society of Pediatric Endocrinology.

Developed in M2PI

Close layer
prev next